New TB Medications, Shorter Regimens Could Transform Treatment For Drug-Resistant Strains

The Lancet: Changing the game for multidrug-resistant tuberculosis
“…New drugs and shorter regimens … could help improve the worrying, global situation for MDR-TB. The current treatment regimen is long and hard on patients, and there is already extensive resistance to existing second-line drugs…” (Ghanashyam, 3/19).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.